OncoMatch/Clinical Trials/NCT06517888
Anti-VEGF Gene Therapy Trial for Vestibular Schwannoma
Is NCT06517888 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies AAVAnc80-antiVEGF via Akouos Delivery Device for vestibular schwannoma.
Treatment: AAVAnc80-antiVEGF via Akouos Delivery Device — This trial will evaluate the safety and tolerability of a single unilateral administration of one of three dose levels of AAVAnc80-antiVEGF and will evaluate the Akouos delivery device to safely achieve the intended product performance.
Check if I qualifyExtracted eligibility criteria
Prior therapy
Cannot have received: surgery
Prior surgery ... for vestibular schwannoma.
Cannot have received: radiation therapy
Prior ... radiation therapy for vestibular schwannoma.
Cannot have received: gene therapy
any prior participation in a gene therapy clinical trial.
Cannot have received: investigational drug
Prior participation in a clinical trial with an investigational drug within six months prior to administration (Day 0)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Johns Hopkins Hospital · Baltimore, Maryland
- Mayo Clinic · Rochester, Minnesota
- Vanderbilt Bill Wilkerson Center · Nashville, Tennessee
- University of Texas Southwestern · Dallas, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify